Varana Capital Leads Arcuro Medical's Series A Financing, Driving Strategic Growth in 2025

Rhea-AI Summary

Varana Capital has led the initial closing of Arcuro Medical's Series A financing round, with participation from Trendlines and Consensus Business Group. The funding will support Arcuro's growth and innovation in the medical device industry, with the Series A remaining open for additional investment.

Arcuro Medical achieved several key milestones in 2024, including establishing a new U.S. organization, expanding distribution partnerships, submitting a 510(k) for a new product line, and surpassing 5,000 global SuperBall cases. The company is positioned for significant growth in 2025 with an enhanced product portfolio and expanded market reach.

The company will present at the MSK Innovations Pitch Event on January 8, 2025, providing investors and stakeholders an opportunity to learn more about their vision and advancements.

Positive

• Secured Series A financing with notable investors
• Achieved 5,000 global SuperBall cases milestone
• Submitted 510(k) for new product line
• Expanded U.S. and international distribution network
• Established new U.S. organization with sales leadership

Negative

• None.

News Market Reaction

+6.92%

1 alert

+6.92% News Effect

On the day this news was published, TRNLY gained 6.92%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

DENVER, Jan. 6, 2025 /PRNewswire/ -- Varana Capital is pleased to announce their role as lead investor in the initial closing of Arcuro Medical's Series A financing round. This funding round, which includes participation from other notable investors, including Trendlines and Consensus Business Group, will support Arcuro's next phase of growth and innovation. The Series A remains open for additional investment, offering further opportunities for stakeholders to join in advancing Arcuro Medical's impactful work in the medical device industry.

"Our investment in Arcuro Medical is a testament to the Varana Capital Chai Fund's mission to support Israeli companies making a global impact," said Varana Capital Co-Founder and CIO Ezra Gardner. "As the largest Israeli opportunity fund, the Chai Fund was created to invest in transformative innovations, and Arcuro's revolutionary medical technology exemplifies this by providing better outcomes for orthopedic injuries. If you know any surgeons specializing in knees, please refer them to us: We are confident we can make a meaningful impact on their practice and, most importantly, their patients' lives."

Jamal Rushdy, Arcuro Medical's CEO, commented, "We are excited and grateful to welcome Varana Capital as the lead investor in our Series A, alongside our valued existing investors. Supported by this funding, our team is enthusiastic to kick off a strong 2025, delivering on our mission to assist surgeons in improving their patient's quality of life."

Arcuro Medical concluded a pivotal 2024 with several key achievements, including:

• Establishing a new U.S. organization and hiring key sales leadership
• Adding new U.S. and international distribution partners
• Achieving a significant product development milestone with the 510(k) submission of a new product line
• Surpassing 5,000 global SuperBall cases

These accomplishments position Arcuro Medical for significant growth as it enters 2025 with an enhanced product portfolio and expanded market reach.

MSK Innovations Pitch Event: A Closer Look at Arcuro Medical

Arcuro Medical will present at the MSK Innovations Pitch Event on Wednesday, January 8, 2025, at 2 PM PST / 5 PM EST. This virtual event provides an excellent opportunity for investors and stakeholders to gain deeper insights into the company's vision and advancements. Interested participants can register [here].

About Arcuro Medical Ltd.

Arcuro Medical Ltd., a portfolio company of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), headquartered in Israel with U.S. operations in Minneapolis, Minnesota and Naples, Florida, was founded by executives with over 40 years' combined experience developing and manufacturing minimally invasive orthopedic products, bringing medical devices from concept to market. Arcuro is expanding its established worldwide distribution network to introduce the SuperBall™ technology to healthcare professionals in every market. The company continues the development of game-changing technologies for sports medicine to improve patients' lives. For more information on Arcuro and its products, visit arcuromedical.com and follow the company on LinkedIn.

About Varana Capital

Founded by Philip Broenniman and Ezra Gardner in 2012, Denver-based Varana Capital, LLC invests in and cooperatively engages with public and private companies, partnering with visionary leaders to create a global impact. For more information, visit Varana Capital's Website, or visit Varana Capital's LinkedIn page.

For media inquiries, please contact Kelci Jones (kmj@varanacapital.com).

View original content:https://www.prnewswire.com/news-releases/varana-capital-leads-arcuro-medicals-series-a-financing-driving-strategic-growth-in-2025-302343121.html

SOURCE Varana Capital, LLC

FAQ

What was the value of Arcuro Medical's Series A financing round in 2025?

The press release does not disclose the specific value of the Series A financing round led by Varana Capital.

How many SuperBall cases has Arcuro Medical completed globally?

Arcuro Medical has surpassed 5,000 global SuperBall cases as of 2024.

When will Arcuro Medical present at the MSK Innovations Pitch Event?

Arcuro Medical will present at the MSK Innovations Pitch Event on Wednesday, January 8, 2025, at 2 PM PST / 5 PM EST.

What key achievements did Arcuro Medical accomplish in 2024?

In 2024, Arcuro Medical established a new U.S. organization, hired key sales leadership, added new distribution partners, submitted a 510(k) for a new product line, and surpassed 5,000 global SuperBall cases.

Who are the investors participating in Arcuro Medical's Series A financing?

The Series A financing is led by Varana Capital, with participation from Trendlines and Consensus Business Group.